A Cohort Study on Biomarkers of Hypertension in Guangdong Province(GDP Study)

Hypertension Clinical Trial

Official title:

Establishing Biobank in a Cohort Study for Hypertensive Patients in Guangdong Province(GDP Study)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04212455
• Other study ID #: 2019343H(R2)
• Status: Recruiting
• Start date: January 1, 2020
• Est. completion date: December 31, 2050

Study information

• Verified date: December 2019
• Source: Guangdong Provincial People's Hospital
• Contact: Feng Ying-qing, PhD
• Phone: 86-2083827812
• Email: 651792209[@]qq.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Hypertension is the most common chronic diseases and a most important risk factor for cardiovascular and cerebrovascular diseases, and also a substantial public health problem. The purpose of the study is to investigate the association between biomarkers and adverse outcomes in patients with hypertension.

Description:

Study population includes subjects who are hypertension, of any race or ethnicity, 18 or older years of age, and have provided written informed consent to provide whole blood specimens at one or more study visits.

Physical examination, questionnaire survey and biological sample collection will be conducted at baseline and the incidence of all-cause and cardiovascular mortality will be investigated during follow-up.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50000
• Est. completion date: December 31, 2050
• Est. primary completion date: December 31, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• =18 years old

• In accordance with the diagnosis of hypertension (including Blood pressure =140/90mmHg and/or taking antihypertensive drugs and/or self-reported hypertension)

Exclusion Criteria:

• <18 years old

• Unsigned informed consent

• Pregnant Women and Lactation

Related Conditions & MeSH terms

• Cardiovascular Diseases
• Hypertension

Intervention

Other:
• Non-interventional study
This is an observational, non-interventional study

Locations

Country	Name	City	State
China	Guangdong Cardiovascular Institute	Guangzhou	Guangdong
China	Guangdong Provincial People's Hospital	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Guangdong Provincial People's Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Secondary outcomes of cardiovascular diseases	The number of and the incidence rate of cardiovascular diseases.	Through study completion, an average of 1 years
Other	Secondary outcomes of cerebrovascular diseases	The incidence rate of cerebrovascular diseases.	Through study completion, an average of 1 years
Other	Secondary outcomes of kidney	The incidence rate of hypertensive renal injure and end-stage renal disease	Through study completion, an average of 1 years
Other	others	Number of participants with reported hospitalization due to other diseases(eg. diabetes, tumor)	From date of inclusion until the date of first event, assessed up to 1 year
Primary	All-Cause Mortality	All-cause mortality was confirmed through a combination of hospital medical records, telephone contacts with patients or family members, and death registration at the Guangdong Provincial Center for Disease Control and Prevention.	From date of inclusion until the date of death from any cause, assessed up to 1 year
Secondary	Cardiovascular Mortality	Cardiovascular mortality was defined as death attributable to an ischemic cardiovascular cause (including fatal MI, stroke).	From date of inclusion until the date of death from any cause, assessed up to 1 year